New drug shows promise for Hard-to-Treat breast cancers in Real-World study

NCT ID NCT07358182

Recruiting now Disease control Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is tracking 300 people with HER2-positive or HER2-low breast cancer who are receiving trastuzumab-rezetecan as part of their routine care. Researchers are monitoring side effects and how well the drug works in real-world conditions, not in a strict lab setting. The goal is to see if this treatment is safe and effective for everyday patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: trastuzumab-rezetecan
What this could lead to: If successful, this could show that trastuzumab-rezetecan is a safe and effective treatment option for people with HER2-positive or HER2-low breast cancer in everyday clinical practice.
What could go wrong: This is an observational study, not a controlled trial, so results may be less reliable. It is also early-stage evidence, and side effects or limited effectiveness could emerge.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2-LOW BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HER2-LOW BREAST CANCER HER2-POSITIVE BREAST CANCER TRASTUZUMAB-REZETECAN

Contacts and locations

Locations

Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University
RECRUITING

Guangzhou, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.